- Home
- ALLE vs EXEL Comparison
ALLE vs EXEL Comparison
Compare ALLE & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLE | EXEL |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 11.4B |
| IPO Year | 2013 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ALLE | EXEL |
|---|---|---|
| Price | $144.07 | $44.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 21 |
| Target Price | ★ $171.13 | $46.45 |
| AVG Volume (30 Days) | 707.0K | ★ 2.0M |
| Earning Date | 04-24-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | 9.09 | ★ 57.95 |
| EPS | ★ 7.44 | 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $8.43 | $13.66 |
| Revenue Next Year | $4.60 | $13.39 |
| P/E Ratio | $19.70 | ★ $16.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $122.14 | $33.76 |
| 52 Week High | $183.11 | $48.74 |
Technical Indicators
Market Signals| Indicator | ALLE | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.09 | 58.52 |
| Support Level | $141.26 | $40.53 |
| Resistance Level | $167.42 | $45.88 |
| Average True Range (ATR) | 3.50 | 1.04 |
| MACD | 0.81 | 0.33 |
| Stochastic Oscillator | 56.51 | 73.68 |
Price Performance
Historical ComparisonAbout ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.